Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study - The Lancet Oncology
By A Mystery Man Writer
Description
Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. - Abstract - Europe PMC
Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet Digital PCR - eBioMedicine
Cancers, Free Full-Text
Cells, Free Full-Text
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance, Journal of Hematology & Oncology
Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial, BMC Cancer
Critical Review of *EGFR*-Mutated NSCLC What We Do and Do Not Know
Critical Review of *EGFR*-Mutated NSCLC What We Do and Do Not Know
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
PDF] Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Current and Future Therapeutics for Patients with Non-small Cell Lung Cancer and Known Activating Mutations in Epidermal Growth Factor Receptor - touchONCOLOGY
Pharmaceutics, Free Full-Text
Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
from
per adult (price varies by group size)